Arbutus stock jumps as Moderna settlement payment deadline nears

Shares of Arbutus Biopharma climbed as investors positioned for an upcoming payment from Moderna tied to a resolved patent dispute over technology used in Moderna’s COVID-19 vaccines.

The market move follows a settlement announced earlier that resolves claims that Moderna used Arbutus’s patented technology without authorization. In the dispute, the central issue involved lipid nanoparticles, or LNPs, the tiny fat-based delivery particles that help mRNA therapies enter human cells and that are critical to the performance of mRNA vaccines such as Moderna’s Spikevax.

According to coverage of the deal, Moderna is required under the agreement to make a $950 million upfront payment by July 8. The total settlement was described as potentially reaching up to $2.25 billion, but the immediate catalyst for traders is the near-term cash transfer tied to the upfront portion.

Arbutus expects to receive approximately $179 million of the July 8 payment after costs, with the remainder of the upfront amount directed to Genevant Sciences, described in the coverage as a unit of Roivant Sciences. Investors appeared to treat Arbutus’s expected net proceeds as a near-term financial inflection point.

The patent litigation backdrop underscores why the agreement matters commercially even years after the pandemic. The coverage said Arbutus had developed and patented specific LNP formulations prior to COVID-19, while Moderna’s vaccines relied on LNP delivery systems to transport mRNA into patients. The settlement was characterized as a resolution to a long-running dispute over whether the technology used in Moderna’s vaccines overlapped with Arbutus’s patents.

Arbutus did not, in the published post, provide additional detail on the timing or mechanics of any subsequent capital-return actions beyond indicating it was evaluating options once the funds arrive. The same coverage said the company plans to consider returning capital to shareholders later this year after receipt of the payment.

Market participants also appeared to focus on the fact that the settlement is not merely theoretical or back-ended. An upfront payment requirement creates a defined window for when cash could land on the balance sheet, which often tightens market expectations ahead of the deadline.

Still, several details remain outside the public snapshot from the post. It does not disclose whether there are conditions that could delay payment, nor does it provide the exact schedule for distribution of proceeds among parties beyond the stated net expectation for Arbutus and the remainder for Genevant Sciences. Investors will likely look for additional confirmation from company disclosures closer to the payment date.